Journal
TRANSPLANTATION
Volume 91, Issue 11, Pages 1173-1176Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0b013e318215e72b
Keywords
Hepatocellular carcinoma; Immunosuppression; mTOR; CNI; Tumor recurrence
Categories
Ask authors/readers for more resources
Effects of immunosuppressive drug on tumor development in transplantation are understudied. Tumors are especially concerning when liver transplantation recipients have a pretransplant hepatocellular carcinoma (HCC). Because immunosuppressive drugs likely influence HCC recurrence, with mammalian target of rapamycin inhibitors showing antineoplastic properties especially experimentally, we sought for practical medical guidance from published clinical studies. Although the current literature review revealed 14 studies regarding immunosuppression in this context, suggesting antitumor effects for mammalian target of rapamycin inhibitors, the quality of evidence is low. Therefore, randomized controlled trials investigating effects of immunosuppression on HCC recurrence in liver transplantation are lacking, exposing a gap between basic science knowledge and clinical evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available